Cargando…
The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
OBJECTIVE: The sodium-glucose transporter 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin are recently approved medications for type 2 diabetes. Recent studies indicate that SGLT2 inhibitors may inhibit the growth of some cancer cells but the mechanism(s) remain unclear. METHODS: Cellular proli...
Autores principales: | Villani, Linda A., Smith, Brennan K., Marcinko, Katarina, Ford, Rebecca J., Broadfield, Lindsay A., Green, Alex E., Houde, Vanessa P., Muti, Paola, Tsakiridis, Theodoros, Steinberg, Gregory R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034684/ https://www.ncbi.nlm.nih.gov/pubmed/27689018 http://dx.doi.org/10.1016/j.molmet.2016.08.014 |
Ejemplares similares
-
Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses
por: Tsakiridis, Evangelia E., et al.
Publicado: (2021) -
Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials
por: Troncone, Michael, et al.
Publicado: (2017) -
Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
por: Biziotis, Olga‐Demetra, et al.
Publicado: (2023) -
The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
por: Ali, Amr, et al.
Publicado: (2023) -
AMPK β1 reduces tumor progression and improves survival in p53 null mice
por: Houde, Vanessa P., et al.
Publicado: (2017)